Mu.Ta.Lig - COST ACTION CA15135

Dr. Gilles HANQUET

14 June 2016


General information

Surname: Gilles
Cell phone number with international prefix: + 33 368852746
Country: France
Affiliation: ECPM Strasbourg, UMR 7509, CNRS, senior scientist
Gender: F □ M X
Year of the PhD title: 1993
Personal web page: http://
Previous COST participation: No □ Yes X      CM0602, CM1609, CM1407


List of 10 selected publications within last 5 years

1.     European. Journal of  Organic. Chemistry. 2010, 27, 5232-5247
2.    European Journal of Organic Chemistry 2011, 28, 2818-2826
3.      Organic Biomolecular. Chemistry. 2012, 10, 9418-9428
4.      Organic.Biomolecular. Chemistry. 2013, 11, 6829-6840
5.    Tetrahedron 2013, 69, 7759-7770
6. Natural. Products. Report. 2014, 31, 468-488
7. Journal of Heterocyclic Chemistry. 2014, 52, 425-439
8. Tetrahedron Letters 2015, 56, 6823-6826.
9. European Journal of Medicinal Chemistry, 2015,103, 105-122 .
10. Chimia, 2016, 70, 20-28.


Main skills and expertise (up to 5)

1.      Total synthesis of natural products
2.      Medicinal chemistry
3.      Development of stereoselective methodologies for chemical synthesis
4.      Stereoselective introduction of Emergent Fluorine Substituents (EFS)


Main equipment/facilities available in the participants’ lab (up to 5)

1.      Everything needed for organic synthesis
2.      GC-MS, HPLC-MS, MW reactor, Glove box, FT-IR spectro,



Short personal activity proposal for the COST Action CA15135 (max 1000 characters)

Brief Description of research topics:

Main interests of my laboratory cover the development of novel methods and strategies for

organic synthesis as well as the total synthesis of biologically active natural products and their

analogues. We focus on highly flexible strategies to obtain as much as possible analogues for

SAR studies.

We propose Total synthesis of biologically relevant natural macrolides and terpenoids, the synthesis of small inhibitors of angiogenesis and cancer stem cells, the enantioselective synthesis of aliphatic building-blocks bearing Emergent Fluorinated Substituents (CHF2-, OCF3– and SF5-containing compounds) for medicinal chemistry purposes.


Brief description of the current main research projects:

We started recently a new program towards the stereoselective preparation of building blocks containing emergent fluorinated substituents (EFS). We currently prepare homologues of pamamycin-607 as antituberculinic agents, amino-oxazole-based inhibitors of Hedgehog pathway (also agonists of Smoothened SAG), quassinoids (SkE) for cancer inhibition (MAP-kinases), and quinoids for cdc-25 inhibition.


Work Group preference: score from 1 (preferred) to 4 (not preferred)

Work Group of the CA15135 COST Action Score
WG1: Development of new chemical entities 1
WG2: Selection of biological targets and assessment of biological data 4
WG3: Development of chemical databases 2
WG4: Development of Computational methods for multiple ligand design and discovery 3